
CAS: 1132709-14-8

((S)-3-Methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxaMido)propanaMido)butyl)boronic acid
CAS:1132709-14-8
Formula:
C19H25BN4O4
Purity:
98%
Color and Shape:
Solid
Molecular weight:
384.2372
Ref: IN-DA008W3I
10mg | 143.00 € | ||
25mg | 204.00 € | ||
50mg | 504.00 € |
Estimated delivery in United States, on Tuesday 15 Apr 2025

Ref: 54-BUP03700
25mg | 676.00 € | ||
50mg | 903.00 € | ||
100mg | 1,212.00 € |
Estimated delivery in United States, on Wednesday 16 Apr 2025

Ref: 4Z-B-4675
5mg | To inquire | ||
10mg | To inquire | ||
25mg | To inquire | ||
50mg | To inquire | ||
100mg | To inquire |
Estimated delivery in United States, on Tuesday 22 Apr 2025

(1S,2S)-Bortezomib
Controlled ProductCAS:1132709-14-8
Impurity Bortezomib USP Impurity G Stability Hygroscopic Applications (1S,2S)-Bortezomib is an isomer of Bortezomib (B675700), …
Formula:
C19H25BN4O4
Color and Shape:
Neat
Molecular weight:
384.24
Ref: TR-B675715
1mg | 360.00 € | ||
10mg | 2,433.00 € |
Estimated delivery in United States, on Tuesday 6 May 2025

(1S,2S)-Bortezomib-d5
Controlled ProductCAS:1132709-14-8
Formula:
C19D5H20BN4O4
Color and Shape:
Neat
Molecular weight:
389.268
Ref: TR-B675717
25mg | 9,793.00 € |
Estimated delivery in United States, on Tuesday 27 May 2025

(1S,2S)-Bortezomib
CAS:1132709-14-8
(1S,2S)-Bortezomib (Bortezomib) is an enantiomer of Bortezomib.
Formula:
C19H25BN4O4
Purity:
98.33%
Color and Shape:
Solid
Molecular weight:
384.24
Ref: TM-T10061
1mg | 64.00 € | ||
2mg | 96.00 € | ||
5mg | 169.00 € | ||
10mg | 284.00 € | ||
25mg | 454.00 € | ||
50mg | 615.00 € | ||
100mg | 827.00 € | ||
1mL*10mM (DMSO) | 172.00 € |
Estimated delivery in United States, on Tuesday 3 Jun 2025

(1S,2S)-Bortezomib
CAS:1132709-14-8
Versatile small molecule scaffold
Formula:
C19H25BN4O4
Purity:
Min. 95%
Molecular weight:
384.24 g/mol
Ref: 3D-HVB70914
1mg | Discontinued | Request information | |
2mg | Discontinued | Request information | |
5mg | Discontinued | Request information | |
10mg | Discontinued | Request information | |
100mg | Discontinued | Request information |